Biocon surges on getting EMA`s nod for new drug product fill finish line for Semglee at Malaysia facility
Biocon is currently trading at Rs. 444.25, up by 9.60 points or 2.21% from its previous closing of Rs. 434.65 on the BSE.
The scrip opened at Rs. 439.80 and has touched a high and low of Rs. 447.00 and Rs. 434.00 respectively. So far 234017 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 5 has touched a 52 week high of Rs. 447.00 on 16-Jul-2026 and a 52 week low of Rs. 331.00 on 11-Aug-2025.
Last one week high and low of the scrip stood at Rs. 447.00 and Rs. 403.00 respectively. The current market cap of the company is Rs. 72016.18 crore.
The promoters holding in the company stood at 44.91%, while Institutions and Non-Institutions held 31.59% and 23.49% respectively.
Biocon has received approval from the European Medicines Agency (EMA) for a new drug product fill finish line for Semglee (insulin glargine) at its insulin manufacturing facility in Malaysia. Supplies to Europe from this line are expected to begin from Q2FY27.
